Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.44 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spizofurone SCHEMBL29493300 | 1.00 | KDM4E (0.46) | KDM4EHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10334515 | 0.86 | HDAC3 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11386477 | 0.84 | PPIB (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13182901 | 0.84 | ATM (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11248254 | 0.81 | CYP1A2 (0.54) | KDM4EHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13158976 | 0.81 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18157491 | 0.79 | S100A4 (0.46) | KDM4ES100A4NPC1RAB9AMAPT | |
| SCHEMBL11248793 | 0.77 | MAPT (0.53) | KDM4EHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11379323 | 0.75 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13481991 | 0.74 | MAPT (0.66) | KDM4ENPC1MAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4690805-A1 | METHODS AND DEVICES FOR INTRA BLOCK COPY AND INTRA TEMPLATE MATCHING | Beijing Dajia Internet Information Technology Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4522159-A1 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | Poviva Corp. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4518846-A1 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | Poviva Corp. (US) | 2025-03-12 | — | — | EP | claimed |
| WO-2025042560-A1 | METHODS AND DEVICES FOR INTRA BLOCK COPY | Beijing Dajia Internet Information Technology Co., Ltd. (CN) | 2025-02-27 | — | — | WO | claimed |
| WO-2025024007-A1 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | POVIVA CORP . (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024213784-A1 | NUTRIENT MEDIUM FOR BIOLUMINESCENT BACTERIA AND DEVICE FOR THE IMPLEMENTATION THEREOF | BRIAND, Germain (FR) | 2024-10-17 | — | — | WO | claimed |
| WO-2024211853-A1 | METHODS AND DEVICES FOR INTRA BLOCK COPY AND INTRA TEMPLATE MATCHING | BEIJING DAJIA INTERNET INFORMATION TECHNOLOGY CO., LTD (CN) | 2024-10-10 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8779870-B2 | Low phase variation CMOS digital attenuator | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-07-15 | — | — | US | claimed |
| US-20130088403-A1 | Low Phase Variation CMOS Digital Attenuator | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-04-11 | — | — | US | claimed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0003084-B1 | SPIROBENZOFURANONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | Takeda Chemical Industries, Ltd. (JP) | 1982-02-24 | — | — | EP | claimed |
| US-4284644-A | Spirobenzofuranone compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | KDM4E 4537/4885HDAC3 1717/4885HDAC4 1996/4885 |
| US-20040009234-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | KDM4E 4537/4885HDAC3 1717/4885HDAC4 1996/4885 |
| US-20040010035-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | KDM4E 4537/4885HDAC3 1717/4885HDAC4 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.